Full Judgment Text
Text read from the judgment PDF published on the High Court's eCourts portal, through the
Indian High Court Judgments open data set (Dattam Labs,
CC BY 4.0).
The court's own copy is the authoritative text.
$~110 to 117
*
IN THE HIGH COURT OF DELHI AT NEW DELHI
+
W.P.(C) 208/2026 and CM APPL. 956-957/2026
CIPLA LIMITED
.....Petitioner
Versus
NATIONAL PHARMACEUTICAL PRICING AUTHORITY &
ANR.
.....Respondents
+
+
+
+
+
+
+
W.P.(C) 209/2026 and CM APPL. 958-959/2026
W.P.(C) 211/2026 and CM APPL. 963-964/2026
W.P.(C) 212/2026 and CM APPL. 965-966/2026
W.P.(C) 213/2026 and CM APPL. 968-969/2026
W.P.(C) 214/2026 and CM APPL. 970-971/2026
W.P.(C) 215/2026 and CM APPL. 973-974/2026
W.P.(C) 227/2026 and CM APPL. 1085-1086/2026
Memo of appearances:
For petitioners:
Ms. Archana Sahadeva, Advocate.
For respondents:
Mr. Nishant Gautam CGSC with Ms.Kavya Shukl, Mr. Vinay Kaushik
Goverment Pleader.
CORAM:
HON'BLE MR. JUSTICE PURUSHAINDRA KUMAR KAURAV
%
1.
ORDER
19.01.2026
This batch of writ petitions involves similar issues and, therefore, is
being decided by a common order.
This is a digitally signed order.
The authenticity of the order can be re-verified from Delhi High Court Order Portal by scanning the QR code shown above.
The Order is downloaded from the DHC Server on 23/01/2026 at 12:28:54
2.
The petitioner i.e., Cipla Limited is a company engaged in the
manufacture of drugs. Respondent no. 1 i.e., National Pharmaceutical
Pricing Authority (Pricing Authority) is a body under the Department of
Pharmaceuticals, Ministry of Chemicals and Fertilisers, and the regulatory
authority for pricing of drugs under the Drugs (Prices Control) Order, 2013
(Control Order, 2013) issued under the Essential Commodities Act, 1955.
Respondent no. 2 is the Department of Pharmaceuticals, Ministry of
Chemicals and Fertilisers.
3.
The grievance of the petitioner is with respect to various Demand
Notices issued by the Pricing Authority, directing the petitioner to deposit
certain sums of money, which the petitioner allegedly received by making
certain batches of drugs available for sale to the public, at rates higher than
are legally permissible.
4.
The Pricing Authority had issued various notifications fixing the
‘ceiling price’ for certain drugs (‘Scheduled Formulations’) specified in
Schedule-I of the Control Order, 2013 in exercise of powers conferred under
paragraphs no. 14, 16 and 17 thereof. On the basis of samples allegedly
obtained from retailers, it found that some of the ‘Scheduled Formulations’
manufactured by the petitioner were being sold at a price higher than their
‘ceiling price’. The Pricing Authority, thereafter, issued Preliminary Notices
directing the petitioner to explain the reasons for non-compliance with the
aforesaid notifications. The petitioner replied to the same, stating that the
batches of the ‘Scheduled Formulations’ which were the subject matter of
the Preliminary Notices were manufactured and sold to dealers/retailers
prior to the notifications of the ‘ceiling price’ and that it had issued revised
price lists along with ‘Form V’. It was stated that issuance of price lists
This is a digitally signed order.
The authenticity of the order can be re-verified from Delhi High Court Order Portal by scanning the QR code shown above.
The Order is downloaded from the DHC Server on 23/01/2026 at 12:28:54
along with ‘Form V’ is sufficient compliance of its obligations as per
paragraph no. 24 of the Control Order, 2013.
5.
Upon consideration of the reply, the Pricing Authority issued the
impugned Demand Notices directing the petitioner to deposit certain sums
of money which, according to it, the petitioner had accrued by overcharging,
along with interest.
6.
On the first date of hearing, i.e., 08.01.2026, Ms. Archana Sachdeva,
learned counsel for the petitioner has placed on record a brief note
indicating, among other particulars, the dates on which the batches which
are the subject matter of the impugned Demand Notices were manufactured,
the ‘ceiling price’-notifications were issued by the Pricing Authority, and the
revised price lists in ‘Form V’ were issued by the petitioner, to emphasise
that the relevant batches of the ‘Scheduled Formulations’ were
manufactured and marketed prior to the issuance of the notifications.
7.
The chart handed over by Ms. Sachdeva, is extracted as under:“BRIEF NOTE ON FACTS”
Item WP (C)
No. No.
Impugned
Batch No. &
date of
manufacturing
by the
Petitioner
208/2026 SA22815; Oct.
Ceiling
Price
Notification
issued by
NPPA
Form V
issued by
Petitioner
on
Date of
alleged
purchase
by the
NPPA
SO No.
194(E); dt.
11.01.2023
SO No.
87(E); dt.
06.01.2023
SO No.
1579(E); dt.
31.03.2023
(w.e.f.
12.01.2023
[PDF 230]
25.05.2023 Forcan
150mg
09.01.2023
[PDF 88]
20.10.2023 Cipmox
CV
02.04.2023
[PDF 112]
21.07.2023 Terbicip
209/2026 AFC22029;
June 2022
211/2026 D2031; April
This is a digitally signed order.
The authenticity of the order can be re-verified from Delhi High Court Order Portal by scanning the QR code shown above.
The Order is downloaded from the DHC Server on 23/01/2026 at 12:28:54
Product
Name
01.04.2023)
SO No.
87(E); dt.
06.01.2023
SO No.
1579(E); dt.
31.03.2023
(w.e.f.
01.04.2023)
SO No.
87(E); dt.
06.01.2023
SO No.
87(E); dt.
06.01.2023
SO No.
194(E); dt.
11.01.2023
212/2026 KO20300;
May 2022
09.01.2023
[PDF 242]
213/2026 23S2GCA145;
Feb. 2023
214/2026 P110458; May
215/2026 SA13292; Nov.
227/2026 G1832022;
Oct. 2022
8.
The Court, thereafter, called upon the respondents to explain as to
02.04.2023
[PDF 121]
25.05.2023 Novamox
CV
625mg
19.07.2023 Itranox
09.01.2023
[PDF 89]
22.08.2023 Fungicip
09.01.2023
[PDF 84]
23.05.2023 Forcan
200mg
12.01.2023
[PDF 103]
25.07.2023 Vitafol
5mg
why the matter should not be remitted back for its fresh consideration.
9.
Mr. Nishant Gautam, learned CGSC, who appears on behalf of the
respondents, on instructions, initially tried to justify the impugned orders by
taking the Court through observations made by the Supreme Court in the
case of M/s Glaxo Smithkline v. Union of India.1 He then contends that this
batch of petitions has its own peculiarity and the Court, therefore, may
consider to pass an appropriate order.
10.
The primary question which requires adjudication is whether the
impugned
Demand
Notices
takes
into
consideration
all
relevant
factors/obligations on the petitioner under paragraph no. 24 of the Control
Order, 2013 and the applicable decisions of the Courts.
11.
Learned counsel for the petitioner submits that the impugned Demand
2014 (2) SCC 753
This is a digitally signed order.
The authenticity of the order can be re-verified from Delhi High Court Order Portal by scanning the QR code shown above.
The Order is downloaded from the DHC Server on 23/01/2026 at 12:28:54
Notices are illegal and arbitrary, and have been made without appreciating
the documentary proof of fulfilment of the obligations of the petitioner
under paragraph no. 24 of the Control Order, 2013. It is also submitted that
the decision passed by the Division Bench of this Court in the case of Cipla
Ltd v. Union of India,2 has not been properly considered by the Pricing
Authority.
12.
It is submitted that the Division Bench of this Court, in the case of
Cipla Ltd., has held that re-labelling of stocks manufactured prior to the date
on which the notifications of ‘ceiling price’ were issued is not obligatory on
the manufacturer and issuance of revised price lists in ‘Form V’ would be
sufficient for fulfilling its obligations under paragraph no. 24 of the Control
Order, 2013. She also submits that when, as per the Pricing Authority,
‘Schedule Formulations’ manufactured by the petitioner were found to be
overpriced on the basis of samples purportedly obtained from retailers, the
impugned Demand Notices ought to have disclosed particulars such as,
where the samples were collected from, and proof of the same actually being
sold at the printed M.R.P. It is also the case of the petitioner that no action
seems to have been taken against the retailers who were, allegedly, selling
the overpriced ‘Scheduled Formulations’.
13.
Mr. Gautam, as noted earlier, has made all possible endeavours to
justify the impugned Demand Notices including to state that there is no
provision for the Pricing Authority to take action against retailers.
According to him, the principles laid down by the Supreme Court as well as
by this Court, have rightly been considered and the impugned Demand
Notices do not warrant any interference.
2015:DHC:9617
This is a digitally signed order.
The authenticity of the order can be re-verified from Delhi High Court Order Portal by scanning the QR code shown above.
The Order is downloaded from the DHC Server on 23/01/2026 at 12:28:54
14.
The Pricing Authority has recorded its reasoning to justify action. In
paragraph no. 5 of the impugned Demand Notices, the following reasoning
has been recorded:
“5. The abovementioned contentions of the company with regard to
overcharging have been examined and it is stated that:
(i) Subject formulation bearing batch no. KO20304 manufactured in the
month o f May-2022 which was available in the market for sale to public on
20.10.2023 at higher MRP of Rs.223.44/- for pack of 10 tablets over and
above the applicable notified ceiling price of Rs.18.30/- per tablet (i.e.
Rs.183/- for 10 tablets on pro rata basis) exclusive of GST vide 5.0.
No.1574(E) dated 31.03.2023 read with 5.0. 4663(E) dated 25.10.2023. This
shows that the company had not implemented the applicable notified ceiling
price on the stocks available in the market/ trade channel.
(ii) It is pertinent to mention that in the judgement of Hon'ble Supreme Court
in Mis Glaxo Smithkline Vs UOI reported in (2013) SCC Vol. II 753, wherein
it was, inter-alia, held that "once the price is notified, it takes immediate
effect from the date of notification and there cannot be two prices at the end
point of the distribution chain depending on the consumer. Consumer must
get the benefit of the notified price. That is the ultimate objective of DPCO.
Mere issuance of Form-V and issuing revised price list does not fulfil the
obligations of the company as a manufacturer/marketer of the formulation
under reference". Hence, the company has to implement the notified ceiling
price on its new manufacturing products as well as to the pre-manufactured
stocks available in the market for sale to public from the date of gazette
notification.
(iii) As per the provisions of DPCO 2013, where any manufacturer sells a
scheduled formulation at a price higher than the ceiling price (plus local
taxes as applicable) fixed and notified by the Government, such
manufacturers shall be liable to deposit the overcharged amount along with
interest thereon from the date of such overcharging. Further, the Hon'ble
Hight Court of Delhi in its judgement in the matter of Cipla Ltd. Vs UoI held
that it would be sufficient compliant on the part of manufacturer if the
manufacturer issue price list/ revised price list and follow paragraph 24 of
the DPCO,2013. The referred Judgement also held that re-labelling of
manufactured stocks prior to the date on which the notifications are issued is
not obligatory. What is necessary is that pharmaceuticals be sold at the
revised price or labelled price, whichever is lower. However, since, the
detected batch was available in the market for sale to public at higher MRP,
this shows that the company had not implemented the notified ceiling price on
the stocks available in the market/ trade channel.
This is a digitally signed order.
The authenticity of the order can be re-verified from Delhi High Court Order Portal by scanning the QR code shown above.
The Order is downloaded from the DHC Server on 23/01/2026 at 12:28:54
In view of above, the company's contentions are found untenable and
therefore, overcharging amount has been calculated considering printed
MRP on the pack as the sample with higher MRP was available in the market
for sale to public.”
(Emphasis supplied)
15.
On careful reading of the same, it appears that the action is solely
based on the decision of the Supreme Court in the case of M/s Glaxo
Smithkline and the Pricing Authority has quoted a purported extract from
the said decision which has been underlined for reference.
16.
It is seen that the liability saddled on the petitioner stems from the
expression, “Mere issuance of Form-V and issuing revised price list does
not fulfil the obligations of the company as a manufacturer/marketer of the
formulation under reference” which is attributed to the Supreme Court.
However, upon careful perusal of the decision, it is seen that the said
expression is conspicuously missing.
17.
It is clear that the Pricing Authority has wrongly construed the
Supreme Court’s decision to the extent of drawing a conclusion that mere
issuance of Form-V and the revised price lists does not fulfil the obligations
of the company as a manufacturer/marketer of the formulation under
reference. If the Pricing Authority intended to convey its own opinion, it
ought to have unequivocally been identified as such. Instead, the Pricing
Authority has projected its own opinion as observations of the Supreme
Court, which is impermissible.
18.
The case of the petitioner is that under paragraph no. 24 of the Control
Order, 2013 manufacturers are only required to issue ‘Form V’ and revised
price lists for pre-manufactured stocks, once the ‘ceiling price’ is notified.
19.
A reading of paragraph no. 24 of the Control Order, 2013 also
nowhere discloses any other obligation to be discharged by manufacturers. It
This is a digitally signed order.
The authenticity of the order can be re-verified from Delhi High Court Order Portal by scanning the QR code shown above.
The Order is downloaded from the DHC Server on 23/01/2026 at 12:28:54
is thus seen that the Pricing Authority has grossly misunderstood the
Supreme Court’s decision in the case of M/s Glaxo Smithkline. The
findings recorded in paragraph no.5 (ii) of the Demand Notices are wholly
perverse.
20.
Furthermore, the decision of the Division Bench of this Court in the
case of Cipla Ltd. has also been considered in the impugned Demand
Notices. The stand taken by the respondents in the said case, that, issuance
of price lists in ‘Form V’ would be sufficient compliance of the petitioner’s
obligations under paragraph no. 24 of the Control Order, 2013 for stocks
manufactured prior to the notifications, and the recall/reprinting of the same
is only optional, was recorded in paragraphs no. 2 and 3 of the said decision.
Though, reference is made to the said decision, however, the Pricing
Authority has not delineated as to how the same would apply to support the
stand of the Pricing Authority.
21.
The Pricing Authority ought to have dealt with the aspect as to how
the petitioner will have to implement the ‘ceiling price’ notifications. There
also does not seem to be any material in the impugned Demand Notices as to
on what basis, it has been concluded that the ‘Scheduled Formulations’ were
actually being sold at excessive price. The Pricing Authority may have been
in actual proof of the same, but it must reflect in the impugned Demand
Notices. If the decision, so taken, does not make reference to such material,
the same may not be relied on to supplement the decision in a Court of law.
Furthermore, the Court in exercise of its power of judicial review of the
decision, may not be able to properly appreciate the circumstances under
which it was made.
22.
Ms. Sachdeva, learned counsel for the petitioner also points out order
This is a digitally signed order.
The authenticity of the order can be re-verified from Delhi High Court Order Portal by scanning the QR code shown above.
The Order is downloaded from the DHC Server on 23/01/2026 at 12:28:54
dated 16.05.2019 passed by this Court in a similar batch of writ petitions,
where, under almost similar circumstances, the matter was remitted back to
the Pricing Authority for its consideration afresh.
23.
Having considered the overall facts and circumstances of the instant
cases, the Court finds that the impugned decision suffers from arbitrariness
and, seems to be based on extraneous considerations. Therefore, the
impugned Demand Notices are set aside.
24.
The Pricing Authority shall be at liberty to treat the instant batch of
writ petitions as representations submitted by the petitioner and adjudicate
the same afresh, with due expedition, after considering the entire material in
view of the issues raised in the instant writ petitions.
25.
If the petitioner, so desires, it may make a request of personal hearing
before the Pricing Authority. If such a request is made, let the same be
considered.
26.
With the aforesaid observations, the instant writ petitions stand
disposed of along with all pending applications.
PURUSHAINDRA KUMAR KAURAV, J
JANUARY 19, 2026
Nc/ amg
This is a digitally signed order.
The authenticity of the order can be re-verified from Delhi High Court Order Portal by scanning the QR code shown above.
The Order is downloaded from the DHC Server on 23/01/2026 at 12:28:54
This page is for informational and research purposes only and does not constitute legal advice.
Consult a qualified advocate for advice specific to your situation.
Is your name in this judgment and should it be masked, or is something on this page wrong?
Request a review